



Inflammation Unleashed in Viral-Induced Epileptogenesis

Epilepsy Currents
2021, Vol. 21(6) 433–440
© The Author(s) 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/15357597211040939
journals.sagepub.com/home/epi
 SAGE

Ana Beatriz DePaula-Silva, PhD¹ , Laura A. Bell, PhD^{1,2} ,
Glenna J. Wallis, BS¹ , and Karen S. Wilcox, PhD^{1,2*}

¹ Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA

² Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT, USA

Correspondence: Karen S. Wilcox, PhD, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA. Email: karen.wilcox@hsc.utah.edu

Abstract

Viral infection of the central nervous system increasingly places people at risk of developing life-threatening and treatment-resistant acute and chronic seizures (epilepsy). The emergence of new human viruses due to ongoing social, political, and ecological changes places people at risk more than ever before. The development of new preventative or curative strategies is critical to address this burden. However, our understanding of the complex relationship between viruses and the brain has been hindered by the lack of animal models that survive the initial infection and are amenable for long-term mechanistic, behavioral, and pharmacological studies in the process of viral-induced epileptogenesis. In this review, we focus on the Theiler's murine encephalomyelitis virus (TMEV) mouse model of viral infection-induced epilepsy. The TMEV model has a number of important advantages to address the quintessential processes underlying the development of epilepsy following a viral infection, as well as fuel new therapeutic development. In this review, we highlight the contributions of the TMEV model to our current understanding of the relationship between viral infection, inflammation, and seizures.

Keywords

Theiler's murine encephalomyelitis virus, temporal lobe epilepsy, mouse model, inflammation, macrophages, microglia, astrocyte, NG2-glia

Epilepsy is a devastating neurological disorder characterized by unprovoked recurrent seizures, affecting more than 70 million people worldwide and can result in comorbidities and disabilities. Furthermore, 30% of people with epilepsy are refractory to the currently available medications.¹ While greater than 50% of the epilepsies have an underlying genetic abnormality, epilepsy can also arise from central nervous system (CNS) insults, such as traumatic brain injury, brain tumors, and CNS infections. These CNS traumas set in motion both acute inflammation and long-term changes which are not well understood and thus hinder the development of treatment approaches to prevent long-term epilepsy. Specifically, brain infections are a significant risk factor for the development of

seizures and epilepsy.^{2,3} Along with bacteria, parasites, and fungi, more than 100 different viruses are capable of causing encephalitis in humans, such as herpes simplex virus type-1 (HSV-1), non-polio picornavirus, Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV), cytomegalovirus (CMV),⁴ and human herpes virus-6 (HHV-6).⁵ Recent reports suggest that SARS-CoV2,⁶ the causative agent of COVID-19, can also cause viral encephalitis.⁷ Viral encephalitis can result in acute seizures, which develop up to 2 weeks after infection, and epilepsy that can manifest months to years following the initial infection. For example, in congenital CMV infection, 7 out of 19 infants developed epilepsy,⁴ and HHV-6 is also associated with seizures and epilepsy development.⁵



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).



To identify new disease-modifying therapies to prevent epilepsy from developing in high-risk groups and/or treat seizures/epilepsy following viral encephalitis, we need to understand the mechanisms underlying seizure development after viral infection. Determining mechanisms often requires the use of pre-clinical animal models. Some groups have used HSV-1 and WNV to study seizures and epilepsy in rodent models; however, a limitation in these studies is the high mortality rate observed in infected animals during the acute phase of the neurotropic infection.^{8,9} Mouse Zika infections also have a high mortality, and only subcutaneous Zika infection of P3 Swiss mice resulted in a survivable infection with behavioral and motor seizures in juvenile mice.^{10,11} Perhaps the most successfully utilized viral infection model of epilepsy is the Theiler's murine encephalomyelitis virus (TMEV) in C57BL/6J mice. Mice infected with TMEV develop seizures shortly after infection that resolve by 8–10 days post-infection. The mice survive the infection, and, following a latent period, many of the mice go on to develop epilepsy. The present review will focus on the TMEV mouse model of infection-induced epilepsy, but will also note how findings related to this model are relevant to consequences of other CNS infections.

TMEV Infection as a Mouse Model of Viral-Induced Acute Seizures and Epilepsy

TMEV is a non-enveloped, single-stranded RNA virus from the cardiovirus genus, picornavirus family. TMEV causes enteric

infection in rodents via fecal-oral route transmission. While these infections are usually asymptomatic or mild, virus can spread to the CNS and cause encephalitis and/or encephalomyelitis. The use of TMEV in experimental models of myocarditis, demyelination, and epilepsy is viral and mouse-strain dependent (reviewed elsewhere¹²⁻¹⁴). In this review, we only focus on the TMEV DA strain in C57BL/6J mice.

In this model (Figure 1A), intracerebral (IC) infection of C57BL/6J mice with TMEV results in acute behavioral seizures between 3 and 8 days post-infection (dpi), followed by a latent period, where no seizures are observed. Around 14 dpi, the virus is cleared from the CNS, presumably due to activation of the adaptive immune response. 30–90 dpi, 50–70% of the mice that experienced acute seizures show a significant decrease in seizure threshold and develop epilepsy.^{15,16} The initial viral titer for the infection determines the percentage of mice that develop acute seizures. Convulsive seizures can be induced by handling during the acute infection period or observed to occur spontaneously via video-electroencephalogram monitoring (Figure 1B). A modified Racine scale is used to score seizure severity, as the seizures are limbic in origin.¹⁷ Handling induced seizures no longer occur after the acute infection period, but spontaneous seizures can develop in 50–70% of the mice that experienced seizures in the acute phase of the infection, reflecting the development of epilepsy.

TMEV has a tropism for the pyramidal neurons of the CA1 and CA2 regions, resulting in extensive neuronal loss in this region of the hippocampus. This mouse model recapitulates




Figure 1. Mouse model of viral-induced epilepsy. (A) C57BL/6J mice are i.c. injected with Theiler's murine encephalomyelitis virus, a neurotropic virus member of the Picornaviridae family that can cause encephalitis in infected mice. Between 3 and 8 days post-infection (d.p.i.), mice develop acute seizures, followed by a latent period in which seizures are no longer observed. Between 30 and 100 d.p.i., some mice that experienced acute seizures develop spontaneous recurrent seizures (epilepsy). (B) Representative electroencephalogram from a phosphate-buffered saline-injected mouse, showing normal electroencephalogram recording, and Theiler's murine encephalomyelitis virus-injected mouse, 5 d.p.i., showing generalized convulsive seizures.

pathological and behavioral features observed in people with temporal lobe epilepsy (TLE),¹⁸ including neuronal loss, astrogliosis, microgliosis, infiltration of peripheral macrophages, cognitive deficits, and anxiety-like behavior. Secretion of pro-inflammatory cytokines, especially by microglia and macrophages, amplify neuroinflammation and alter neuronal excitation leading to seizures during the acute infection period (Figure 2). Thus, this model offers an opportunity to understand how inflammation and infection lead to epilepsy. This review will focus on the acute phase of the infection, when seizures are quite prevalent.

Innate Immune Response

Upon viral invasion of the CNS, activation of the innate and adaptive immune response is critical to control viral replication and spread. Following TMEV infection, the innate immune response is activated within hours, and both failure in controlling viral infection and persistent immune response activation can exacerbate CNS inflammation. When mice deficient in TNF-RI, TNF- α , or IL-6 are infected with TMEV, the incidence of seizures is significantly decreased.^{17,19} In addition,

increased levels of the pro-inflammatory cytokines IL-6 and TNF- α are also observed in the serum and in the brains of TMEV-infected mice and in the serum of TLE patients. Therefore, these 2 cytokines may play an integral role in contributing to seizure activity.

The 2 primary innate immune cells that participate in the immune response to TMEV infection of the CNS are microglia and macrophages. However, other glial cells such as astrocytes²⁰ and NG2 cells^{21,22} can also influence the innate response. Looking at microglia and macrophages in TMEV-infected chimeric mice, Cusick et al.²³ demonstrated that while IL-6 is mainly produced by infiltrating macrophages, microglia produce high levels of TNF- α during the acute phase of the infection. Interestingly, inhibition of TNF- α during the acute phase of the ZIKV infection prevented hyperexcitation in mouse brains and decreased seizures,¹⁰ thus elevated TNF- α is likely to be a common cytokine observed during encephalitis.

γ -aminobutyric acid (GABA) is the principal inhibitory neurotransmitter, and decreased GABAergic inhibition in the CA3 region of the hippocampus is found in TMEV-infected mice during the acute infection period.²⁴ α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid type glutamate receptors




Figure 2. Neuroinflammation paradigm in the development of Theiler's murine encephalomyelitis virus-induced encephalitic seizures and epilepsy. In the Theiler's murine encephalomyelitis virus model of infection-induced epilepsy, Theiler's murine encephalomyelitis virus infects pyramidal neurons in the CA1 and CA2 region of the hippocampus. Viral replication causes large-scale neuronal death and damage. Microglia are the initial responders to infection in the brain and contribute to the infiltration of peripheral macrophages. Together, these immune cells release a combination of cytokine damage signals that initiate reactivity of other glial cells, such as NG2-glia, and astrocytes. Glial reactivity contributes to release or increased concentration of a variety of soluble factors that can cause overactivation of AMPA receptors on neurons, leading to increased neuronal damage, and sustained overproduction of cytokines. This cyclical pattern of neuron-glia-immune cell interactions initiates hyperexcitability and seizures in this model.



(AMPA receptors) are associated with excitatory neurotransmission, and CA3 neurons show increased excitation during the acute phase of TMEV infection. While evidence supports the idea that TNF- α increases AMPAR expression in the hippocampus of TMEV-infected mice,¹⁷ IL-6 was shown to decrease cell surface expression of GABAR in a rat study.²⁵ Thus, the cytokines secreted during infection may contribute to enhanced excitation and decreased inhibition and lead to a more seizure prone state.

Peripheral macrophages are not found in the CNS parenchyma unless there is a CNS injury and the BBB is damaged.^{26,27} While microglia are considered the “macrophages of the brain,” these cells are transcriptionally and functionally distinct from peripheral macrophages.²⁸⁻³⁰ Microglia and macrophages are heterogeneous and highly plastic cells, meaning they can rapidly change their phenotypic state based on microenvironment stimuli. Simplistically, these cells can acquire pro-inflammatory and anti-inflammatory phenotypes, characterized by the secretion of pro- and anti-inflammatory mediators, respectively. Activation of microglia and polarization toward an inflammatory state, together with infiltration of inflammatory macrophages into the CNS, are hallmarks of neuroinflammation. Their roles in viral encephalitis-induced epilepsy, along with that of NG2-glia and astrocytes, are discussed below.

Microglia

In TMEV-infected mice, microglia acquire a reactive state and secrete pro-inflammatory cytokines that highly influence seizure development. Interestingly, seizure incidence and severity were not affected in TMEV-infected mice depleted of microglia; however, these mice could not control viral infection, developed paralysis, and had fatal encephalitis that was independent of the viral titer used in the initial infection, suggesting that microglia have a particular role in controlling viral infection and participating in the adaptive immune response.^{31,32} TNF- α expression in the brain of TMEV-infected mice was not affected by microglia depletion, suggesting that CNS and/or infiltrating cells other than microglia are also secreting this cytokine.³² Similarly, mice lacking microglia died during the acute phase of MHV infection.³³ Additional studies in animal models demonstrate that microglia exert an antiviral role during ZIKV, HSV, MHV, and VSV infections.³⁴ While microglia are key to resolution of infection, they also contribute to increased cytokine expression that can lead to increased hyperexcitability. Thus, therapies designed to reduce the impact of microglia cytokine production need to be carefully designed so as not to impair viral clearance.

Macrophages

Macrophages are derived from monocytes originated from bone marrow hematopoietic stem cells. While they are primarily found in the periphery, CNS border-associated macrophages are found in the choroid plexus and meninges.³⁵⁻³⁷ Under physiological conditions, the BBB limits the access of peripheral

immune cells to the CNS; however, disruption of the BBB and secretion of chemokines allow these cells to migrate into the CNS, contributing to neuroinflammation.^{38,39} The macrophage chemoattractant factor C-C motif ligand 2 (CCL2) is produced by several CNS cells such as microglia, neurons, astrocytes, and endothelial cells. CCL2 signals via the C-C motif chemokine receptor 2 (CCR2), expressed by circulating inflammatory monocytes, resulting in the recruitment of monocytes/macrophages into the brain. Notably, CCL2 is significantly upregulated in the brains of people with epilepsy,^{40,41} and in the brains of animals with epilepsy^{42,43}; similarly, a high number of infiltrating macrophages is found in the hippocampus of drug-resistant TLE patients and the hippocampus from patients who died after status epilepticus,⁴⁴ pointing to a substantive role for macrophages in neuroinflammation and seizure/epilepsy pathogenesis. Also, increased infiltration of peripheral macrophages into the brain is found during encephalitis in Simian immunodeficiency virus (SIV)-infected monkeys and WNV encephalitis.⁴⁵ Therefore, macrophage recruitment to the CNS appears to be a common outcome of CNS infection.

In the TMEV model, infiltration of macrophages from the periphery occurs as early as 3 days post-infection.^{23,46} Once in the CNS, macrophages secrete high levels of IL-6²³ and seizure frequency is drastically reduced when macrophages are depleted from mice before TMEV infection.^{46,47} These data support the role of macrophages in seizure generation. Similarly, reduced seizure incidence was observed by limiting CNS macrophage infiltration and inflammation followed by treatment with the anti-inflammatory drugs wagonin and minocycline.²³ Interestingly, knock out of CCR2, which inhibits macrophage migration to the CNS, although it did not prevent seizures from occurring in TMEV-infected mice, reduced seizure severity and inhibited hippocampal damage.⁴⁸ Comparing results from the depletion and migration studies may imply that (a) infiltration of macrophages into the CNS, alone, is not sufficient to drive seizures and (b) activation of macrophages and secretion of pro-inflammatory cytokines by these cells in the periphery could be sufficient to alter glial function, promote CNS inflammation, and decrease seizure threshold. However, these hypotheses remain to be tested. In addition, the mechanisms and signaling pathways activated in macrophages that contribute to its inflammatory phenotype and how it directly affects glial function and neuronal excitation is still unknown.

Using flow cytometry, microglia and macrophages can be discriminated by CD45 level of expression (microglia is CD45^{low}CD11b⁺, while macrophages as CD45^{hi}CD11b⁺).^{12,23,49} However, for a direct visualization method (e.g., IHC), distinct markers are required. While CCR2 can be utilized to label inflammatory infiltrating macrophages,^{50,51} proteins found to be specifically expressed by microglia, such as P2RY12 and TMEM119, can be downregulated during inflammatory conditions,^{52,53} and TMEM119 can also be expressed by macrophages.^{52,54-56} Despite advancements in technology such as single-cell RNA sequencing, it remains difficult to differentiate between microglia and macrophages that have infiltrated the brain.^{28,53,57-59}



NG2

NG2-glia are a glial cell-type known to react to a variety of CNS infectious diseases. Although primarily known for their role as being oligodendrocyte precursor cells, adult animals maintain an abundant population of NG2-glia whose functions, aside from being progenitors of oligodendrocytes, remain largely unknown. NG2-glia are shown to react to CNS injury and infection, though participation within the inflammatory milieu can range from being the primary target of infection, such as during persistent infections causing chronic demyelinating disease such as TMEV infection of SJL mice^{60,61} or Human herpes virus,^{62,63} or as responders to infection and participants in the overall inflammatory responses and mechanisms of brain protection, such as in ZIKV infection⁶⁴ or TMEV infection of C57B/L6J mice in the viral infection-induced model of TLE.

Reactive NG2-glia are shown to undergo morphological and functional changes that may contribute to epileptogenesis following TMEV infection.²¹ Recent studies indicate that NG2-glia are in part responsible for maintaining microglia homeostasis, and dysregulation of NG2-glia signaling to microglia during inflammation and disease heavily exacerbates the pro-inflammatory response,²² a key factor driving seizure development. Additionally, NG2-glia are known to deposit the highly negatively charged NG2 protein, otherwise known as chondroitin sulfate proteoglycan 4 (CSPG4), which, when embedded in the dense extracellular matrix of the glial scar, likely contributes to long-term disruptions in intracellular and extracellular ion homeostasis.⁶⁵⁻⁶⁷ Moreover, disruption in ion homeostasis can affect the transmembrane chloride gradient and the excitatory or inhibitory nature of GABAergic neurotransmission, which can, in turn, facilitate the development of seizure activity.^{62,68,69} Because of their significant roles in contributing to network function and homeostasis, targeting physiological functions of NG2-glia following viral infection may be a way to reduce the sustained inflammatory changes that facilitate epileptogenesis. How and why NG2-glia react is important for considering how the nervous system protects us from pathogens and in considering how to prevent and protect brain structures that are sensitive to inflammatory damage and circuit rewiring that can lead to the development of epilepsy.

Astrocytes

Since astrocytes play many critical roles in normal CNS function, alterations in these cells due to CNS infection can lead to serious neurological complications. Astrocytes support a functional BBB, regulate glutamate homeostasis, participate in innate and adaptive immune responses to viral infections, and express many pattern recognition molecules such as toll-like receptors, chemokines, and cytokines.²⁰ They can also be the target cell of many viruses such as JEV, WNV, and, HIV-1. Astrocyte reactivity to infection is linked to increased BBB permeability, peripheral immune cell infiltration, and CNS inflammation.⁷⁰ Also, glutamate excitotoxicity is associated with CNS viral infection. In TMEV-infected mice, persistent

astrogliosis is observed and altered expression of ion channels and glutamate transporters may contribute to the development of long-term changes in network excitability that lead to chronic epilepsy.^{71,72} However, whether reactive astrocytes have a causative role in the development of epilepsy remains uncertain. Interestingly, in a genetic mouse model of chronic astrogliosis, in which CNS inflammation and BBB dysfunction are not present, spontaneous seizures were observed,⁷³ suggesting astrocytes play a role in seizure development, but further studies are required.

Conclusions and Future Directions

CNS infections are associated with seizures and epilepsy. Viral infections can alter brain homeostasis leading to glial activation, breakdown of the BBB, immune cell infiltration, and neuro-inflammation resulting in neuronal excitation and seizure development. The use of animal models to study epilepsy has contributed extensively to the field of neuroscience, especially in regards to elucidating functional changes in neurons during epilepsy. The mouse model of TMEV-induced seizures/epilepsy has been critical in studying acquired epilepsy and elucidating roles for different brain resident and peripheral immune cells in both inflammation and seizure development. However, the mechanisms of how these cell types contribute to seizures/epilepsy are still not fully understood. Also, studies on microbiota-gut-brain axis suggest that the gut microbiota can also regulate CNS inflammation and function.⁷⁴⁻⁷⁶ It is unknown whether and how changes in the microbiota can modulate seizures induced by TMEV infection. Further mechanistic investigation is therefore necessary and may set the stage for identifying novel disease-modifying targets.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIH/NINDS R37NS065434 (KSW) and the National Science Foundation Graduate Fellowship (LAB).

ORCID iDs

Ana Beatriz DePaula-Silva  <https://orcid.org/0000-0002-2452-3215>
 Laura A. Bell  <https://orcid.org/0000-0003-0659-5650>
 Glenna J. Wallis  <https://orcid.org/0000-0001-6001-8796>
 Karen S. Wilcox  <https://orcid.org/0000-0003-2660-8826>

References

1. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med*. 2011;365(10):919-926. doi:10.1056/NEJMra1004418.
2. Bonello M, Solomon T, Michael BD. Infective causes of epilepsy. *Semin Neurol*. 2015;35(3):235-244. doi:10.1055/s-0035-1552619.



3. Singhi P. Infectious causes of seizures and epilepsy in the developing world. *Dev Med Child Neurol.* 2011;53(7):600-609. doi:10.1111/j.1469-8749.2011.03928.x.
4. Suzuki Y, Toribe Y, Mogami Y, Yanagihara K, Nishikawa M. Epilepsy in patients with congenital cytomegalovirus infection. *Brain Dev.* 2008;30(6):420-424. doi:10.1016/j.braindev.2007.12.004.
5. Bartolini L, Theodore WH, Jacobson S, Gaillard WD. Infection with HHV-6 and its role in epilepsy. *Epilepsy Res.* 2019;153:34-39. doi:10.1016/j.epilepsyres.2019.03.016.
6. Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. *J Neurol Neurosurg Psychiatry.* 2000;68(4):405-415. doi:10.1136/jnnp.68.4.405.
7. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. *Lancet Neurol.* 2020;19(9):767-783. doi:10.1016/S1474-4422(20)30221-0.
8. Getts DR, Matsumoto I, Müller M, et al. Role of IFN-gamma in an experimental murine model of West Nile virus-induced seizures. *J Neurochem.* 2007;103(3):1019-1030. doi:10.1111/j.1471-4159.2007.04798.x.
9. Wu H-M, Huang C-C, Chen S-H, et al. Herpes simplex virus type 1 inoculation enhances hippocampal excitability and seizure susceptibility in mice. *Eur J Neurosci.* 2003;18(12):3294-3304. doi:10.1111/j.1460-9568.2003.03075.x.
10. Nem de Oliveira Souza I, Frost PS, França JV, et al. Acute and chronic neurological consequences of early-life Zika virus infection in mice. *Sci Transl Med.* 2018;10(444):eaar2749. doi:10.1126/scitranslmed.aar2749.
11. Pinheiro DJLL, Oliveira LF, Souza INO, et al. Modulation in phase and frequency of neural oscillations during epileptiform activity induced by neonatal Zika virus infection in mice. *Sci Rep.* 2020;10(1):6763. doi:10.1038/s41598-020-63685-2.
12. DePaula-Silva AB, Hanak TJ, Libbey JE, Fujinami RS. Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: models for multiple sclerosis and epilepsy. *J Neuroimmunol.* 2017;308:30-42. doi:10.1016/j.jneuroim.2017.02.012.
13. Gerhauser I, Hansmann F, Ciurkiewicz M, Löscher W, Beineke A. Facets of theiler's murine encephalomyelitis virus-induced diseases: an update. *Int J Mol Sci.* 2019;20(2):448. doi:10.3390/ijms20020448.
14. Libbey JE, Fujinami RS. Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus. *Future Virol.* 2011;6(11):1339-1350. doi:10.2217/fvl.11.107.
15. Stewart K-AA, Wilcox KS, Fujinami RS, White HS. Theiler's virus infection chronically alters seizure susceptibility. *Epilepsia.* 2010;51(8):1418-1428. doi:10.1111/j.1528-1167.2009.02405.x.
16. Stewart K-AA, Wilcox KS, Fujinami RS, White HS. Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. *J Neuropathol Exp Neurol.* 2010;69(12):1210-1219. doi:10.1097/NEN.0b013e3181ff6420.
17. Patel DC, Wallis G, Dahle EJ, et al. Hippocampal TNF α signaling contributes to seizure generation in an infection-induced mouse model of limbic epilepsy. *eNeuro.* 2017;4(2):0105-0117. doi:10.1523/ENEURO.0105-17.2017.
18. Libbey JE, Kirkman NJ, Smith MCP, et al. Seizures following picornavirus infection. *Epilepsia.* 2008;49(6):1066-1074. doi:10.1111/j.1528-1167.2008.01535.x.
19. Kirkman NJ, Libbey JE, Wilcox KS, White HS, Fujinami RS. Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. *Epilepsia.* 2010;51(3):454-464. doi:10.1111/j.1528-1167.2009.02390.x.
20. Priego N, Valiente M. The potential of astrocytes as immune modulators in brain tumors. *Front Immunol.* 2019;10:1314. doi:10.3389/fimmu.2019.01314.
21. Bell LA, Wallis GJ, Wilcox KS. Reactivity and increased proliferation of NG2 cells following central nervous system infection with Theiler's murine encephalomyelitis virus. *J Neuroinflammation.* 2020;17(1):369. doi:10.1186/s12974-020-02043-5.
22. Zhang S-z, Wang Q-q, Yang Q-q, et al. NG2 glia regulate brain innate immunity via TGF-beta2/TGFBR2 axis. *BMC Med.* 2019;17(1):204. doi:10.1186/s12916-019-1439-x.17
23. Cusick MF, Libbey JE, Patel DC, Doty DJ, Fujinami RS. Infiltrating macrophages are key to the development of seizures following virus infection. *J Virol.* 2013;87(3):1849-1860. doi:10.1128/JVI.02747-12.
24. Smeal RM, Fujinami R, White HS, Wilcox KS. Decrease in CA3 inhibitory network activity during Theiler's virus encephalitis. *Neurosci Lett.* 2015;609:210-215. doi:10.1016/j.neulet.2015.10.032.
25. Garcia-Oscos F, Salgado H, Hall S, et al. The stress-induced cytokine interleukin-6 decreases the inhibition/excitation ratio in the rat temporal cortex via trans-signaling. *Biol Psychiatry.* 2012;71(7):574-582. doi:10.1016/j.biopsych.2011.11.018.
26. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol.* 2018;18(4):225-242. doi:10.1038/nri.2017.125.
27. Zengeler KE, Lukens JR. Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders. *Nat Rev Immunol.* 2021;21:454-468. doi:10.1038/s41577-020-00487-7.
28. DePaula-Silva AB, Gorbea C, Doty DJ, et al. Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation. *J Neuroinflammation.* 2019;16(1):152. doi:10.1186/s12974-019-1545-x.
29. Ochocka N, Segit P, Walentynowicz KA, et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. *Nat Commun.* 2021;12(1):1151. doi:10.1038/s41467-021-21407-w.
30. Savarin C, Dutta R, Bergmann CC. Distinct gene profiles of bone marrow-derived macrophages and microglia during neurotropic coronavirus-induced demyelination. *Front Immunol.* 2018;9:1325. doi:10.3389/fimmu.2018.01325.
31. Sanchez JMS, DePaula-Silva AB, Doty DJ, Truong A, Libbey JE, Fujinami RS. Microglial cell depletion is fatal with low level picornavirus infection of the central nervous system. *J Neurovirol.* 2019;25(3):415-421. doi:10.1007/s13365-019-00740-3.
32. Waltl I, Käufer C, Gerhauser I, et al. Microglia have a protective role in viral encephalitis-induced seizure development and hippocampal damage. *Brain Behav Immun.* 2018;74:186-204. doi:10.1016/j.bbi.2018.09.006.
33. Wheeler DL, Sariol A, Meyerholz DK, Perlman S. Microglia are required for protection against lethal coronavirus encephalitis in mice. *J Clin Invest.* 2018;128(3):931-943. doi:10.1172/JCI97229.



34. Chen Z, Zhong D, Li G. The role of microglia in viral encephalitis: a review. *J Neuroinflammation*. 2019;16(1):76. doi:10.1186/s12974-019-1443-2.
35. Goldmann T, Wieghofer P, Jordão MJC, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. *Nat Immunol*. 2016;17(7):797-805. doi:10.1038/ni.3423.
36. Korin B, Ben-Shaanan TL, Schiller M, et al. High-dimensional, single-cell characterization of the brain's immune compartment. *Nat Neurosci*. 2017;20(9):1300-1309. doi:10.1038/nn.4610.
37. Mrdjen D, Pavlovic A, Hartmann FJ, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. *Immunity*. 2018;48(2):380-395. doi:10.1016/j.immuni.2018.01.011
38. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. *Fluids Barriers CNS*. 2020;17(1):69. doi:10.1186/s12987-020-00230-3.
39. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun*. 2017;60:1-12. doi:10.1016/j.bbi.2016.03.010.
40. Aronica E, Gorter JA. Gene expression profile in temporal lobe epilepsy. *Neuroscientist*. 2007;13(2):100-108. doi:10.1177/1073858406295832.
41. Wu Y, Wang X, Mo X, et al. Expression of monocyte chemoattractant protein-1 in brain tissue of patients with intractable epilepsy. *Clin Neuropathol*. 2008;27(2):55-63. doi:10.5414/npp27055.
42. Foresti ML, Arisi GM, Katki K, Montañez A, Sanchez RM, Shapiro LA. Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. *J Neuroinflammation*. 2009;6:40. doi:10.1186/1742-2094-6-40.
43. Manley NC, Bertrand AA, Kinney KS, Hing TC, Sapolsky RM. Characterization of monocyte chemoattractant protein-1 expression following a kainate model of status epilepticus. *Brain Res*. 2007;1182:138-143. doi:10.1016/j.brainres.2007.08.092.
44. Broekaart DWM, Anink JJ, Baayen JC, et al. Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression. *Epilepsia*. 2018;59(10):1931-1944. doi:10.1111/epi.14550.
45. Ashhurst TM, Vreden C, Munoz-Erazo L, et al. Antiviral macrophage responses in flavivirus encephalitis. *Indian J Med Res*. 2013;138(5):632-647.
46. DePaula-Silva AB, Sonderegger FL, Libbey JE, Doty DJ, Fujinami RS. The immune response to picornavirus infection and the effect of immune manipulation on acute seizures. *J Neurovirol*. 2018;24(4):464-477. doi:10.1007/s13365-018-0636-2.
47. Waltl I, Käufer C, Bröer S, et al. Macrophage depletion by liposome-encapsulated clodronate suppresses seizures but not hippocampal damage after acute viral encephalitis. *Neurobiol Dis*. 2018;110:192-205. doi:10.1016/j.nbd.2017.12.001.
48. Käufer C, Chhatbar C, Bröer S, et al. Chemokine receptors CCR2 and CX3CR1 regulate viral encephalitis-induced hippocampal damage but not seizures. *Proc Natl Acad Sci U S A*. 2018;115(38):E8929-E8938. doi:10.1073/pnas.1806754115.
49. Li Q, Lan X, Han X, Wang J. Expression of Tmem119/Sall1 and Ccr2/CD69 in FACS-sorted microglia- and monocyte/macrophage-enriched cell populations after intracerebral hemorrhage. *Front Cell Neurosci*. 2018;12:520. doi:10.3389/fncel.2018.00520.
50. Howe CL, LaFrance-Corey RG, Goddery EN, Johnson RK, Mirchia K. Neuronal CCL2 expression drives inflammatory monocyte infiltration into the brain during acute virus infection. *J Neuroinflammation*. 2017;14(1):238. doi:10.1186/s12974-017-1015-2.
51. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. *J Immunol*. 2012;188(1):29-36. doi:10.4049/jimmunol.1100421.
52. Bennett ML, Bennett FC, Liddel SA, et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A*. 2016;113(12):E1738-E1746. doi:10.1073/pnas.1525528113.
53. Sousa C, Golebiewska A, Poovathingal SK, et al. Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. *EMBO Rep*. 2018;19(11). doi:10.15252/embr.201846171.
54. Bennett FC, Bennett ML, Yaqoob F, et al. A combination of ontogeny and CNS environment establishes microglial identity. *Neuron*. 2018;98(6):1170-1183. doi:10.1016/j.neuron.2018.05.014.
55. Cronk JC, Filiano AJ, Louveau A, et al. Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. *J Exp Med*. 2018; 215(6):1627-1647. doi:10.1084/jem.20180247.
56. Shemer A, Grozovski J, Tay TL, et al. Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge. *Nat Commun*. 2018; 9(1):5206. doi:10.1038/s41467-018-07548-5.
57. Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity*. 2019; 50(1):253-271. doi:10.1016/j.immuni.2018.11.004.
58. Masuda T, Sankowski R, Staszewski O, Prinz M. Microglia heterogeneity in the single-cell Era. *Cell Rep*. 2020;30(5): 1271-1281. doi:10.1016/j.celrep.2020.01.010.
59. Zheng J, Ru W, Adolacion JR, et al. Single-cell RNA-seq analysis reveals compartment-specific heterogeneity and plasticity of microglia. *iScience*. 2021;24(3):102186. doi:10.1016/j.isci.2021.102186.
60. Jin W, Leitzen E, Goebels S, Nave KA, Baumgärtner W, Hansmann F. Comparison of Theiler's murine encephalomyelitis virus induced spinal cord and peripheral nerve lesions following intracerebral and intraspinal infection. *Int J Mol Sci*. 2019;20(20): 5134. doi:10.3390/ijms20205134.
61. Pringproa K, Rohn K, Kummerfeld M, Wewetzer K, Baumgärtner W. Theiler's murine encephalomyelitis virus preferentially infects immature stages of the murine oligodendrocyte precursor cell line BO-1 and blocks oligodendrocytic differentiation in vitro. *Brain Res*. 2010;1327:24-37. doi:10.1016/j.brainres.2010.02.068.
62. Campbell A, Hogestyn JM, Folts CJ, et al. Expression of the human herpesvirus 6A latency-associated transcript U94A disrupts human oligodendrocyte progenitor migration. *Sci Rep*. 2017;7(1): 3978. doi:10.1038/s41598-017-04432-y.



63. Levine JM, Enquist LW, Card JP. Reactions of oligodendrocyte precursor cells to alpha herpesvirus infection of the central nervous system. *Glia*. 1998;23(4):316-328.
64. Schultz V, Barrie JA, Donald CL, et al. Oligodendrocytes are susceptible to Zika virus infection in a mouse model of perinatal exposure: Implications for CNS complications. *Glia*. 2021;69(8):2023-2036. doi:10.1002/glia.24010.
65. Nayak T, Trotter J, Sakry D. The intracellular cleavage product of the NG2 proteoglycan modulates translation and cell-cycle kinetics via effects on mTORC1/FMRP signaling. *Front Cell Neurosci*. 2018;12:231. doi:10.3389/fncel.2018.00231.
66. Sakry D, Neitz A, Singh J, et al. Oligodendrocyte precursor cells modulate the neuronal network by activity-dependent ectodomain cleavage of glial NG2. *PLoS Biol*. 2014;12(11):e1001993. doi:10.1371/journal.pbio.1001993.
67. Sakry D, Trotter J. The role of the NG2 proteoglycan in OPC and CNS network function. *Brain Res*. 2016;1638(Pt B):161-166. doi:10.1016/j.brainres.2015.06.003.
68. Dzhala V, Valeeva G, Glykys J, Khazipov R, Staley K. Traumatic alterations in GABA signaling disrupt hippocampal network activity in the developing brain. *J Neurosci*. 2012;32(12):4017-4031. doi:10.1523/JNEUROSCI.5139-11.2012.
69. Staley KJ, Dudek FE. Interictal spikes and epileptogenesis. *Epilepsy Curr*. 2006;6(6):199-202. doi:10.1111/j.1535-7511.2006.00145.x.
70. Soung A, Klein RS. Viral encephalitis and neurologic diseases: focus on astrocytes. *Trends Mol Med*. 2018;24(11):950-962. doi:10.1016/j.molmed.2018.09.001.
71. Loewen JL, Barker-Haliski ML, Dahle EJ, White HS, Wilcox KS. Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy. *J Neuropathol Exp Neurol*. 2016;75(4):366-378. doi:10.1093/jnen/nlw008.
72. Vezzani A, Auvin S, Ravizza T, Aronica E. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds *Jasper's Basic Mechanisms of the Epilepsies*, 2012.
73. Robel S, Buckingham SC, Boni JL, et al. Reactive astroglia causes the development of spontaneous seizures. *J Neurosci*. 2015;35(8):3330-3345. doi:10.1523/JNEUROSCI.1574-14.2015.
74. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. *Physiol Rev*. 2019;99(4):1877-2013. doi:10.1152/physrev.00018.2018.
75. Dahlin M, Prast-Nielsen S. The gut microbiome and epilepsy. *EBioMedicine*. 2019;44:741-746. doi:10.1016/j.ebiom.2019.05.024.
76. Şafak B, Altunan B, Topçu B, Eren Topkaya A. The gut microbiome in epilepsy. *Microb Pathog*. 2020;139:103853. doi:10.1016/j.micpath.2019.103853.